Eli Lilly And Co vs Snap Inc — how do they compare? Eli Lilly And Co trades at $1,215.6 (market cap $1.10T), while Snap Inc trades at $5.51 (market cap $9.05B). The key difference: Eli Lilly And Co is far larger — about 121.5× Snap Inc's market cap, and Eli Lilly And Co pays a 0.56% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| LLY | SNAP | |
|---|---|---|
Market Cap | $1.10T | $9.05B |
Sector | Health | Media |
52-Week High | $1.24K | $9.09 |
52-Week Low | $639.43 | $3.93 |
Enterprise Value | $1.14T | $10.61B |
Dividend Yield | 0.56% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →